Management of Ewing sarcoma family of tumors: Current scenario and unmet need.
Ewing sarcoma family tumors (ESFT) are heterogeneous, aggressive group of disease with peak incidence in adolescent and young adults. The outcome has been improved dramatically from 10% with surgery and radiotherapy alone to 65%-70% now, in localized disease, with the introduction of chemotherapy. Chemotherapy regimen evolved from single agent to multiagent with effort of many cooperative clinical trials over decades. The usual treatment protocol include introduction of multi-agent chemotherapy in neoadjuvant setting to eradicate systemic disease with timely incorporation of surgery and/or radiotherapy as local treatment modality and further adjuvant chemotherapy to prevent recurrence. Risk adapted chemotherapy in neoadjuvant and adjuvant setting along with radiotherapy has been used in many international collaborative trials and has resulted in improved outcome, more so in patients with localized disease. The role of high dose chemotherapy with stem cell rescue is still debatable. The outcome of patients with metastatic disease is dismal with long term outcome ranges from 20%-40% depending on the sites of metastasis and intensity of treatment. There is a huge unmet need to improve outcome further, more so in metastatic setting. Novel therapy targeting the molecular pathways and pathogenesis of ESFT is very much required. Here we have discussed the current standard of management in patients with ESFT, investigational targeted or novel therapies along with future promises.
Bivas Biswas, Sameer Bakhshi, Department of Medical Oncology, Dr.B.R.A.I.R.C.H, All India Institute of Medical Sciences, New Delhi 110029, India.
Bivas
B
Biswas
Bivas Biswas, Sameer Bakhshi, Department of Medical Oncology, Dr.B.R.A.I.R.C.H, All India Institute of Medical Sciences, New Delhi 110029, India.
Sameer
S
Bakhshi
Chemotherapy; Ewing sarcoma; Outcome; Prognostic factors; Radiotherapy; Review; Targeted therapy
Pediatr Blood Cancer. 2007 Feb;48(2):132-9
16317751
Mol Endocrinol. 2012 Sep;26(9):1603-16
22798295
Ann Oncol. 1993;4 Suppl 1:45-58
8338795
Natl Cancer Inst Monogr. 1981 Apr;(56):255-62
7029293
Hum Reprod Update. 2004 May-Jun;10(3):251-66
15140872
Cancer. 2002 Jan 15;94(2):561-9
11900241
Cancer Res. 2012 Apr 1;72 (7):1608-13
22287547
N Engl J Med. 2005 Jul 7;353(1):58-63
15941849
J Clin Oncol. 1996 Apr;14(4):1245-51
8648380
Pediatr Blood Cancer. 2006 Nov;47(6):795-800
16411206
Clin Orthop Relat Res. 2007 Jun;459:40-7
17414166
Pediatr Hematol Oncol. 2015 Feb;32(1):50-9
25252096
J Bone Joint Surg Am. 2014 May 21;96(10):841-9
24875025
J Clin Oncol. 2001 Jun 1;19(11):2812-20
11387352
J Clin Endocrinol Metab. 2006 May;91(5):1723-8
16492690
Int J Radiat Oncol Biol Phys. 1998 Aug 1;42(1):125-35
9747829
Strahlenther Onkol. 2002 Jan;178(1):25-31
11977388
Eur J Cancer. 1999 Nov;35(12):1698-704
10674016
Pediatr Blood Cancer. 2010 Jul 1;54(7):909-15
20405511
Br J Cancer. 2001 Nov 30;85(11):1646-54
11742482
Int J Cancer. 2012 Nov 1;131(9):2153-64
22323082
Pediatr Blood Cancer. 2014 Nov;61(11):1925-31
25132242
N Engl J Med. 2003 Feb 20;348(8):694-701
12594313
Pediatr Blood Cancer. 2006 Jul;47(1):22-9
16572419
Skeletal Radiol. 2011 Aug;40(8):1007-15
21298431
J Clin Oncol. 2010 Jul 10;28(20):3284-91
20547982
Biochim Biophys Acta. 2004 Sep 20;1704(2):49-57
15363860
Pediatr Blood Cancer. 2005 Apr;44(4):338-47
15503297
Fetal Pediatr Pathol. 2012 Jun;31(3):159-63
22413993
Ann Oncol. 2006 Aug;17(8):1301-5
16782749
J Clin Oncol. 1998 Sep;16(9):3044-52
9738574
Pediatr Blood Cancer. 2004 Sep;43(3):229-36
15266406
J Clin Oncol. 2005 Dec 1;23(34):8828-34
16314643
J Clin Oncol. 1992 Sep;10(9):1407-12
1517783
Cancer Res. 2010 Oct 1;70(19):7610-9
20841471
Oncology. 2003;65 Suppl 2:99-104
14586158
Ann Oncol. 2011 May;22(5):1221-7
21059639
J Clin Oncol. 2013 Aug 20;31(24):3034-43
23857966
Diagn Mol Pathol. 1998 Jun;7(3):152-7
9836070
Pediatr Blood Cancer. 2009 Dec;53(6):1029-34
19637327
N Engl J Med. 2005 Jul 21;353(3):318-21
15983020
Br J Cancer. 2012 Mar 13;106(6):1123-33
22374462
Pediatr Blood Cancer. 2015 Mar;62(3):445-9
25346208
J Cancer Res Clin Oncol. 1987;113(2):187-91
3558454
Sarcoma. 2012;2012:301975
23226965
Gynecol Oncol. 1984 Jul;18(3):373-9
6430756
Clin Nucl Med. 2011 Nov;36(11):973-7
21975382
Pediatr Blood Cancer. 2013 Sep;60(9):E97-9
23625700
J Clin Oncol. 2000 Sep;18(17):3108-14
10963639
Cancer. 2010 Apr 15;116(8):1964-73
20151425
Hum Reprod. 1996 Aug;11(8):1620-6
8921104
J Clin Oncol. 2006 Aug 20;24(24):3838-43
16921035
J Surg Oncol. 2015 May;111(6):683-9
25557999
Eur J Cancer. 2004 Jan;40(1):73-83
14687792
Eur J Cancer. 2012 Jun;48(9):1376-85
22516209
Fertil Steril. 1995 Nov;64(5):987-90
7589647
Cancer. 2007 Feb 15;109(4):767-75
17238190
Surgery. 1994 Jun;115(6):687-93
8197559
Bull Cancer. 2001 Jun;88(6):561-70
11459702
Cancer. 2015 Feb 1;121(3):467-75
25251206
Int J Gynecol Pathol. 1990;9(3):231-52
2373588
J Clin Oncol. 1990 Sep;8(9):1514-24
2099751
J Clin Oncol. 2006 Aug 20;24(24):3997-4002
16921053
J Clin Oncol. 2012 Nov 20;30(33):4148-54
23091096
J Clin Oncol. 2014 Aug 10;32(23):2440-8
24982464
Ann Oncol. 2012 Nov;23(11):2970-6
22771824
Pediatr Blood Cancer. 2013 Oct;60(10 ):1621-5
23776128
Bone Marrow Transplant. 2008 May;41(10):867-72
18246113
Eur J Cancer. 1995 Jun;31A(6):999-1001
7646936
Laryngoscope. 2015 Mar;125(3):E112-7
25345585
Oncologist. 2012;17(3):321
22363068
J Clin Oncol. 2009 May 20;27(15):2536-41
19349548
Clin Oncol (R Coll Radiol). 2014 Nov;26(11):722-9
24919857
Hum Reprod. 2010 Jul;25(7):1708-12
20472912
Ann Oncol. 2008 Apr;19(4):814-20
17998282
Int J Radiat Oncol Biol Phys. 2003 Jan 1;55(1):168-77
12504050
J Clin Oncol. 2008 Sep 20;26(27):4385-93
18802150
Eur J Cancer. 2006 Jan;42(1):91-6
16326096
Clin Cancer Res. 2004 Feb 1;10 (3):840-8
14871959
Cancer Discov. 2014 Nov;4(11):1342-53
25223734
Eur J Cancer. 1997 Jun;33(7):1061-9
9376188
Front Oncol. 2012 May 29;2:54
22662320
Nature. 1992 Sep 10;359(6391):162-5
1522903
Neoplasia. 2011 Feb;13(2):145-53
21403840
J Clin Oncol. 2010 Apr 20;28(12):1989-94
20308669
J Surg Oncol. 2010 Apr 1;101(5):389-95
20119985
Cell Cycle. 2011 Oct 1;10(19):3397-408
21926473